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Objective: To estimate the cost-effectiveness of three alternative dietetic strategies for cow’s 
milk allergy in Brazil: 1) using an extensively hydrolyzed casein formula (eHCF;  Nutramigen) 
as a first-line formula, but switching to an amino acid formula (AAF) if infants remain symp-
tomatic; 2) using an AAF as a first-line formula and then switching to an eHCF after 4 weeks 
once infants are symptom-free, but switching back to an AAF if infants become symptomatic; 
and 3) using an AAF as a first-line formula and keeping all infants on that formula. The analy-
sis was conducted from the perspective of the Brazilian public health care system, Sistema 
Único de Saude.
Methods: Decision modeling was used to estimate the probability of immunoglobulin E 
(IgE)-mediated and non-IgE-mediated allergic infants developing tolerance to cow’s milk by 
12 months from starting a formula. The models also estimated the Sistema Único de Saude cost 
(at 2013/2014 prices) of managing infants over 12 months after starting a formula, as well as 
the relative cost-effectiveness of each of the dietetic strategies.
Results: The probability of developing tolerance to cow’s milk by 12 months from starting a 
formula was higher among infants with either IgE-mediated or non-IgE-mediated allergy who 
were initially fed with an eHCF, compared with those who were initially fed with an AAF. The 
total health care cost of initially feeding an eHCF to cow’s milk allergic infants was less than 
that of initially feeding both IgE-mediated and non-IgE-mediated infants with an AAF.
Conclusion: Within the study’s limitations, using an eHCF instead of an AAF for the first-line 
management of newly-diagnosed infants with cow’s milk allergy affords a cost-effective use of 
publicly funded resources, since it improves the outcome for less cost.
Keywords: amino acid formula, Brazil, cost-effectiveness, cow’s milk allergy, extensively 
hydrolyzed formula
Introduction
Cow’s milk allergy (CMA) is an immunologically mediated reaction to the proteins in 
cow’s milk1 and is the most common food allergy in Brazil.2 CMA has an estimated 
annual prevalence of 0.02–0.03 in children <1 year of age.3 The affected children 
generally acquire tolerance to cow’s milk proteins within the first 5 years of life,4 
although the allergy can persist until late in life.5,6 Elimination of cow’s milk proteins 
from a child’s diet and challenge tests are essential for diagnosing and treating this 
allergy,7 and for infants this necessitates the use of a hypoallergenic formula instead 
of standard infant formulas.7
In a recent observational study in Italy, an extensively hydrolyzed casein for-
mula (eHCF; Nutramigen) was found to accelerate the development of tolerance 
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to cow’s milk in infants with CMA compared to those who 
received an amino acid formula (AAF).8 Otherwise healthy 
cow’s milk allergic infants without comorbidities were 
prescribed a formula by a family paediatrician or general 
physician. Then, 15–30 days after starting the formula, the 
infants were referred to a tertiary pediatric allergy center 
for a double-blind, placebo-controlled food challenge 
(DBPCFC) to confirm the diagnosis of CMA. Tolerance to 
cow’s milk was assessed at 12 months from the start of the 
formula by a full anamnestic and clinical evaluation, skin 
prick test, atopy patch test, and oral food challenge. Clinical 
acquisition of tolerance was defined by the presence of a 
negative DBPCFC over a 7-day postchallenge observational 
period. Infants with negative DBPCFC were reevaluated 
after 6 months to validate the persistence of tolerance to 
cow’s milk.8 After 12 months, significantly more infants 
fed with an eHCF (43.6%) were found to have developed 
oral tolerance to cow’s milk, compared to those fed with 
an AAF (18.2%).8 Data from this study (kindly provided 
by the study’s authors) were used for decision modeling 
to estimate the relative cost-effectiveness of using differ-
ent first-line formulas for managing cow’s milk allergic 
infants in Italy.9
There has been much discussion in Brazil about general 
pediatricians initially treating all infants presenting with 
the symptoms of CMA with an AAF and then switching 
to an extensively hydrolyzed formula once infants become 
symptom-free. Notwithstanding this, the comparative health 
economic impact of extensively hydrolyzed formulas and 
AAFs in Brazil is unknown, and therefore, dietetic choices 
are based largely on their safety, nutritional value, and pur-
chase cost. Hence, the objective of the current study was 
to amend the Italian decision models9 to estimate the cost-
effectiveness of using three alternative dietetic strategies in 
Brazil, from the perspective of the Brazilian public health care 
system, Sistema Único de Saude (SUS): 1) using an eHCF 
as a first-line formula, but switching to an AAF if infants 
remain symptomatic; 2) using an AAF as a first-line formula 
and then switching to an eHCF after 4 weeks once infants 
are symptom-free, but switching back to an AAF if infants 
become symptomatic; and 3) using an AAF as a first-line 
formula and keeping all infants on that formula.
Methods
Economic model
The Italian decision models (as previously described9) were 
adapted to reflect the structure of the health care system in Bra-
zil and the context in which CMA is managed in this country. 
Similarly, patients’ pathways and resource use were adapted 
using estimates derived from a panel of general pediatricians 
(n=9), pediatric gastroenterologists (n=13), and pediatric aller-
gists (n=9). The models considered three dietetic strategies: 
1) using an eHCF as a first-line formula, but switching to an 
AAF if infants remain symptomatic; 2) using an AAF as a 
first-line formula and then switching to an eHCF after 4 weeks 
once infants are symptom-free, but switching back to an AAF 
if infants become symptomatic (eHCF-AAF); and 3) using 
an AAF as a first-line formula and keeping all infants on that 
formula. The period of the models was up to 12 months from 
starting a formula or when an infant developed tolerance to 
cow’s milk if that occurred sooner. Ethical approval and patient 
consent were not required as this was an economic modeling 
study and not a patient cohort analysis.
Model inputs – clinical outcomes
The models were populated with data from an observational 
study (as previously described).8,9 The probability of infants 
developing tolerance to cow’s milk at different time points 
was calculated from the percentages of infants who developed 
oral tolerance to cow’s milk after being fed with a formula, 
as previously described for our Italian models.9
Model inputs – resource use
The models were populated with estimates of health care 
resource use pertaining to the management of infants with 
CMA in Brazil. These estimates were based on the clinical 
experiences of 31 pediatricians (Table 1).
The general pediatricians who participated in this study 
each see a mean of <70 infants with suspected CMA per 
annum, with a mean age at presentation of ~3 months (range 
1–6 months). According to these pediatricians, 85% of 
infants with immunoglobulin E (IgE)-mediated allergy and 
15% of those with non-IgE-mediated allergy are expected 
to be referred to a pediatric specialist (ie, gastroenterologist 
or allergist) for further investigations and confirmation of 
diagnosis. The pediatric gastroenterologists who participated 
in this study each see a mean of 70 infants with CMA per 
annum, compared to 30 infants per annum seen by the pedi-
atric allergists. The mean age at presentation to a specialist 
was estimated to be ~4 months (range 2–7 months).
All the pediatricians would recommend a cow’s milk 
elimination diet and prescribe a substitute formula for the 
affected infants. At the initial visit to a general pediatrician, 
60% of infants would generally be prescribed an extensively 
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Table 1 Estimates from pediatricians
Resource use IgE-mediated infants Non-IgE-mediated infants
Percentage upon initial presentation to a GP 20 80
Percentage managed by a PG 20 80
Percentage managed by a PA 75 25
Percentage referred by a GP to a PG 10 10
Percentage referred by a GP to a PA 75 5
Percentage referred by a PG to a PA 50 0
Percentage referred by a PA to a PG 0 20
Mean number of visits to a GP in months 1–3 following initial presentation 4 4
Mean number of visits to a GP in months 4–6 following initial presentation 3 3
Mean number of visits to a GP in months 7–12 following initial presentation 5 5
Mean number of visits to a PG in months 1–3 following initial presentation 3 3
Mean number of visits to a PG in months 4–6 following initial presentation 2 2
Mean number of visits to a PG in months 7–12 following initial presentation 3 3
Mean number of visits to a PA in months 1–3 following initial presentation 3 3
Mean number of visits to a PA in months 4–6 following initial presentation 2 2
Mean number of visits to a PA in months 7–12 following initial presentation 3 3
Percentage managed by a GP who also see a nutritionist 25 25
Percentage managed by a PG who also see a nutritionist 65 65
Percentage managed by a PA who also see a nutritionist 65 65
Percentage managed by a GP who undergo a skin prick test 10 10
Percentage managed by a GP who undergo a radioallergosorbent test/ImmunoCAP 40 40
Percentage managed by a GP who undergo an atopy patch test 10 10
Percentage managed by a GP who undergo a stool (α-1-antitrypsin) test 35 35
Percentage managed by a GP who undergo an ultrasound 5 5
Percentage managed by a GP who undergo an endoscopy 2 2
Percentage managed by a GP who undergo a placebo-controlled food challenge 0 0
Percentage managed by a PG who undergo a skin prick test 15 15
Percentage managed by a PG who undergo a radioallergosorbent test/ImmunoCAP 40 40
Percentage managed by a PG who undergo an atopy patch test 1 1
Percentage managed by a PG who undergo a stool (α-1-antitrypsin) test 0 0
Percentage managed by a PG who undergo an ultrasound 0 0
Percentage managed by a PG who undergo an endoscopy 20 20
Percentage managed by a PG who undergo a placebo-controlled food challenge 0 0
Percentage managed by a PA who undergo a skin prick test 60 60
Percentage managed by a PA who undergo radioallergosorbent test/ImmunoCAP 75 75
Percentage managed by a PA who undergo an atopy patch test 20 20
Percentage managed by a PA who undergo a stool (α-1-antitrypsin) test 1 1
Percentage managed by a PA who undergo an ultrasound 0 0
Percentage managed by a PA who undergo an endoscopy 5 5
Percentage managed by a PA who undergo a placebo-controlled food challenge 5 5
Percentage prescribed a proton pump inhibitor by a GP 10 10
Percentage prescribed an H2 antagonist by a GP 0 0
Percentage prescribed domperidone by a GP 15 15
Percentage prescribed emollients by a GP 40 40
Percentage prescribed a systemic corticosteroid by a GP 0 0
Percentage prescribed a topical corticosteroid by a GP 20 20
Percentage prescribed an antihistamine by a GP 35 35
Percentage prescribed a proton pump inhibitor by a PG <1 <1
Percentage prescribed an H2 antagonist by a PG <1 <1
Percentage prescribed domperidone by a PG 0 0
Percentage prescribed emollients by a PG 25 25
Percentage prescribed a systemic corticosteroid by a PG 0 0
Percentage prescribed a topical corticosteroid by a PG <1 <1
Percentage prescribed an antihistamine by a PG <1 <1
Percentage prescribed a proton pump inhibitor by a PA 5 5
Percentage prescribed an H2 antagonist by a PA 0 0
Percentage prescribed domperidone by a PA 0 0
Percentage prescribed emollients by a PA 55 55
Percentage prescribed a systemic corticosteroid by a PA 5 5
Percentage prescribed a topical corticosteroid by a PA 30 30
Percentage prescribed an antihistamine by a PA 65 65
Abbreviations: GP, general pediatrician; IgE, immunoglobulin E; PA, pediatric allergist; PG, pediatric gastroenterologist.
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hydrolyzed formula. The other infants would receive either a 
soy-based formula, a partially hydrolyzed formula, or AAF. 
Over 95% of infants referred to a pediatric allergist would 
generally be prescribed an extensively hydrolyzed formula 
at the first visit. In contrast, an estimated one-third of infants 
would be prescribed an extensively hydrolyzed formula at 
the first visit to a pediatric gastroenterologist. The other two-
thirds would be prescribed an AAF at the first visit and would 
generally remain on that formula. In addition, an estimated 
20% of infants would be prescribed a proton pump inhibitor 
or prokinetic for ~7 days, 40% an emollient for 6–12 months, 
20% a corticosteroid for ~7 days, and 40% an antihistamine 
for up to 1 month.
The interviewed pediatricians prescribe formula based on 
an infants’ age and weight. Therefore, the prescribed volumes 
that have been incorporated in models were consistent with 
the estimates previously described for our Italian study.9
Model outputs
The primary measure of clinical effectiveness was the prob-
ability of infants developing tolerance to cow’s milk by 12 
months from starting a formula.
Unit costs in Brazilian Real at 2013/2014 prices 
(Table 2)10,11 were assigned to the estimates of resource use 
in the models in order to calculate the cost of health care 
resource use funded by the SUS over 12 months from the 
start of a formula.
The models were used to estimate the relative cost-
effectiveness of the three dietetic strategies in terms of the 
“incremental cost per additional infant who developed toler-
ance to cow’s milk by 12 months from starting a formula” 
in Brazil. This was calculated using a previously described 
methodology,9 as the difference between the expected costs 
of two alternative dietetic strategies divided by the difference 
between the expected outcomes of the alternative strategies 
in terms of the probability of developing tolerance to cow’s 
milk. If one of the dietetic strategies improved the prob-
ability of developing tolerance to cow’s milk for less cost, it 
was considered to be the dominant (cost-effective) dietetic 
strategy. The analysis was conducted from the perspective of 
the SUS.
Sensitivity analyses
Probabilistic sensitivity analyses were undertaken (10,000 
iterations of each model) by simultaneously varying the 
probabilities, clinical outcomes, resource use values, and 
unit costs within the models to assess uncertainty in the 
results. The distributions used were similar to those pre-
viously described for our Italian models.9 Using the out-
puts from these analyses, an estimation was made of the 
probability of being cost-effective at different thresholds 
of incremental cost per additional infant who developed 
tolerance to cow’s milk by 12 months from starting a 
formula.
Deterministic sensitivity analyses were also performed 
to identify how the incremental cost-effectiveness of the 
alternative dietetic strategies would change by varying 
different model inputs. The budget impact and resource 
implications of starting the infants with each of the dietetic 
strategies under investigation compared with current prac-
tice were also estimated for the annual cohort of newly-
diagnosed infants with CMA in Brazil.
Results
Probability of developing tolerance to 
cow’s milk
The probability of developing tolerance to cow’s milk was 
higher among infants who were initially fed with an eHCF 
(Figure 1). Also, the probability of developing tolerance 
to cow’s milk was higher among those infants with non-
IgE-mediated CMA compared to those with IgE-mediated 
allergy.
Table 2 Unit costs in R$ at 2013/2014 prices
Resource Unit cost (R$)
Clinician visits
 Pediatrician visit 10.00
 Pediatric gastroenterologist visit 10.00
 Pediatric allergist visit 10.00
Tests  
 Skin prick test 1.77
 Radioallergosorbent test 9.25
 Atopy patch test 1.77
 Stool test 3.68
 Ultrasound 37.95
 Endoscopy 48.16
 Food challenge 10.00
Formulae (per 400 g can)  
 eHCF 58.00
 AAF 123.00
Drugs (per 7 days treatment)  
 Proton pump inhibitors 26.88
 Prokinetics 5.14
 Topical corticosteroids 3.62
 Systemic corticosteroids 4.62
 Antihistamines 11.25
Note: Data from Ministry of Health (Brazilian SUS – SIGTAP)10 and Brasindice.11
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein 
formula; R$, Brazilian Real.
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Figure 1 Expected probability of infants developing tolerance to cow’s milk by 12 months from starting a formula.
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E.
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Health care resource use and 
corresponding costs
Use of health care resources is expected to be less among 
infants who are initially managed with an eHCF compared 
to those managed with the other dietetic strategies (Table 3). 
Hence, the total health care cost of initially feeding infants 
with an eHCF was estimated to be less than that of feeding 
infants with an AAF (Table 3). Furthermore, initially feed-
ing infants with an eHCF instead of an AAF is expected to 
free up health care resources for alternative use by other 
patients.
Cost-effectiveness analyses
Of the three dietetic strategies, use of an eHCF resulted in 
the lowest 12-month cost from the start of a formula and the 
highest probability of developing tolerance to cow’s milk 
among both IgE-mediated and non-IgE-mediated allergic 
infants (Table 4). Hence, initial feeding with an eHCF was 
Table 3 Expected levels of health care resource use and corresponding costs in R$ at 2013/2014 prices over 12 months from starting 
a formula
eHCF AAF–eHCF AAF
IgE-mediated Non-IgE-
mediated
IgE-mediated Non-IgE-
mediated
IgE-mediated Non-IgE-
mediated
Mean resource use per patient
Number of visits to a pediatrician 2.6 9.0 13.2 13.3 2.6 9.9
Number of visits to a pediatric specialist 7.4 1.4 0.8 0.2 7.6 1.6
Number of skin prick tests 0.7 0.2 <0.1 <0.1 0.7 0.2
Number of radioallergosorbent tests 1.1 0.5 0.1 <0.1 1.2 0.6
Number of atopy tests 0.3 0.1 <0.1 <0.1 0.3 0.1
Mean cost of health service 
resource use per patient (R$) 
Clinician visits 99.39 104.75 139.91 134.29 102.09 114.39
Tests 15.60 10.22 1.60 1.06 16.03 10.59
Prescribed drugs 34.67 52.64 11.57 13.36 34.67 52.64
Prescribed formula 5,093.07 4,709.46 5,639.27 5,255.66 10,110.60 9,844.92
Total 5,242.73 4,877.07 5,792.35 5,404.37 10,263.39 10,022.54
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; R$, Brazilian Real.
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Table 4 Cost-effectiveness of eHCF versus AAF-eHCF and eHCF versus AAF at 12 months after starting a formula
Dietetic strategy Expected SUS 
cost per patient 
over 12 months
Expected probability of 
acquiring tolerance to 
cow’s milk by 12 months
Expected 
SUS cost 
difference
Expected difference 
in probability of 
acquiring tolerance 
to cow’s milk
Incremental cost for 
each additional infant 
acquiring tolerance to 
cow’s milk
IgE-mediated infants
eHCF R$ 5,243 0.24
AAF–eHCF R$ 5,792 0.20
−R$ 549 0.04 Dominated
AAF R$ 10,263 0
−R$ 4,471 0.20 Dominated
Non-IgE-mediated 
infants
eHCF R$ 4,877 0.56
AAF–eHCF R$ 5,404 0.52
−R$ 527 0.04 Dominated
AAF R$ 10,023 0.32
−R$ 4,619 0.20 Dominated
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; R$, Brazilian Real; SUS, Sistema Único de Saude.
found to be a dominant strategy when compared to starting 
feeding with an AAF (Table 4).
Sensitivity analyses
Probabilistic sensitivity analyses were performed (Figure 2A 
and B) to estimate the distribution of expected SUS cost 
differences between the alternative dietetic strategies over 
12 months from starting a formula and expected differences in 
the probability of developing tolerance to cow’s milk between 
the alternative dietetic strategies by 12 months. Using these 
distributions, it was estimated that the  probability of an 
eHCF being cost-effective compared to an AAF–eHCF and 
an AAF was 0.62 and 0.84, respectively, and the  probability 
of an AAF–eHCF being cost-effective compared to an AAF 
was 0.81 at all cost-effectiveness thresholds, for both IgE-
mediated and non-IgE-mediated allergic infants.
Deterministic sensitivity analyses (Table 5) demonstrated 
that changes in the probability of  developing tolerance to 
cow’s milk at different time points can potentially change the 
results. So too can changes in the number of cans of formula 
being prescribed. However, the relative cost-effectiveness of 
the three dietetic strategies was not sensitive to changes in 
any other model input.
Budget impact and resource implications 
of managing CMA
There are an estimated 2.83 million live births in Brazil per 
annum,12 and the annual incidence of CMA is reported to be 
0.025.13 Hence, there are an estimated 70,750 new CMA-
affected infants per annum in Brazil. Using the distribution 
of formula use estimated from the interviewed pediatricians, 
current management of all 70,750 newly-diagnosed infants 
was estimated to result in 42% of the cohort developing tol-
erance to cow’s milk by 12 months from starting a formula, 
and a cost to the SUS of R$ 476.3 million (Table 6). If all 
these infants were initially managed with an eHCF, it is 
expected that 50% of the cohort would develop tolerance to 
cow’s milk and there would be 24,500 fewer visits to general 
pediatricians, 2,800 fewer visits to pediatric specialists, 700 
fewer diagnostic tests, and a 27% cost reduction to the SUS 
of R$ 126.9 million. If all these infants were initially man-
aged with an AAF followed by an eHCF (AAF–eHCF), it is 
expected that 46% of the cohort would develop tolerance to 
cow’s milk and there would be 383,700 more visits to general 
pediatricians, 147,200 fewer visits to pediatric specialists, 
58,500 fewer diagnostic tests, and a 19% cost reduction to 
the SUS of R$ 88.9 million. If all these infants were initially 
managed with an AAF and not switched to an extensively 
hydrolyzed formula, it is expected that 26% of the cohort 
would develop tolerance to cow’s milk and there would be 
45,400 more visits to general pediatricians, 5,200 more visits 
to pediatric specialists, 1,500 more diagnostic tests, and a 
49% cost increase to the SUS of R$ 235.6 million.
Discussion
This study assessed the cost-effectiveness of using three 
alternative dietetic strategies for managing cow’s milk aller-
gic infants in Brazil. The analysis was based on the only 
comparative analysis of an eHCF with an AAF that was 
available at the time of performing this study, which had 
separately assessed tolerance acquisition to cow’s milk in 
IgE-mediated and non-IgE-mediated allergic infants.8 This 
comparative analysis was an observational study in which the 
dietary effect of each formula was measured under controlled 
conditions. Nevertheless, the infants were not randomized 
to their formula, sample sizes were small in absolute terms 
and unbalanced between the groups, and resource use was 
not recorded.8 The study’s authors made every attempt to 
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overcome the nonrandomized study design and account for 
any baseline differences between the groups.8 The inher-
ent uncertainty of using data from this observational study 
was addressed, to some extent, by our extensive sensitivity 
analyses.
The relative cost-effectiveness of an eHCF in Brazil is 
consistent with the findings from our recent studies in Spain 
and Italy, which also found that initial use of an eHCF as a 
first-line management for CMA was cost-effective when com-
pared with an AAF.9,14 We also found that in clinical  practice 
Figure 2 (A) Scatterplot of the incremental cost-effectiveness of: 1) eHCF versus AAF–eHCF, 2) eHCF versus AAF, and 3) AAF–eHCF versus AAF among IgE-mediated 
allergic infants, generated by 10,000 iterations of the model. (B) Scatterplot of the incremental cost-effectiveness of: 1) eHCF versus AAF–eHCF, 2) eHCF versus AAF, and 
3) AAF–eHCF versus AAF among non-IgE-mediated allergic infants, generated by 10,000 iterations of the model.
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; R$, Brazilian Real.
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Table 6 Budget impact analysis over 12 months following initial presentation to a general pediatrician and starting a formula
 Manage all 70,750 infants with:
Current practice eHCF AAF–eHCF AAF
Total number of pediatrician visits 550,900 526,400 934,600 596,300
Total number of pediatric gastroenterologist visits 47,400 46,100 5,600 49,700
Total number of pediatric allergist visits 119,000 117,500 13,600 121,900
Total number of skin prick tests 17,000 16,800 1,700 17,400
Total number of immunoCAP tests 39,000 38,600 4,000 39,900
Total number of atopy patch tests 9,200 9,100 1,000 9,400
Total cost (R$ million) 476.3 349.4 387.4 711.9
Percentage of infants who acquire tolerance to cow’s milk 42% 50% 46% 26%
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein formula; R$, Brazilian Real.
Table 5 Deterministic sensitivity analyses
Scenario Formula Range in expected probability of 
developing tolerance to cow’s milk
Range in expected SUS cost per 
patient
IgE-mediated 
infants
Non-IgE-mediated 
infants
IgE-mediated 
infants
Non-IgE-
mediated infants
Probability of developing tolerance to cow’s 
milk at different time points ranges from 
20% below to 20% above the base case value
eHCF 0.17–0.31 0.43–0.70 R$ 6,200–4,200 R$ 5,900–3,800
AAF–eHCF 0.13–0.27 0.41–0.68 R$ 6,700–4,900 R$ 6,400–4,400
AAF 0.08–0.12 0.26–0.38 R$ 10,300–10,200 R$ 10,100–9,900
Number of follow-up visits to a general 
pediatrician ranges from 50% below to 50% 
above the base case value
eHCF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
AAF–eHCF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
AAF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Number of follow-up visits to a pediatric 
specialist ranges from 50% below to 50% 
above the base case value
eHCF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
AAF–eHCF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
AAF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Number of diagnostic tests ranges from 50% 
below to 50% above the base case value
eHCF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
AAF–eHCF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
AAF Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Unchanged from 
baseline
Number of cans of formula ranges from 50% 
below to 50% above the base case value
eHCF Unchanged from 
baseline
Unchanged from 
baseline
R$ 4,200–6,300 R$ 3,900–5,800
AAF–eHCF Unchanged from 
baseline
Unchanged from 
baseline
R$ 4,700–6,900 R$ 4,300–6,400
AAF Unchanged from 
baseline
Unchanged from 
baseline
R$ 8,400–12,500 R$ 8,000–12,000
Abbreviations: AAF, amino acid formula; eHCF, extensively hydrolyzed casein formula; IgE, immunoglobulin E; R$, Brazilian Real; SUS, Sistema Único de Saúde.
in the US and UK, more cow’s milk allergic infants who 
were initially fed with an eHCF were successfully managed, 
compared to those who were fed with an AAF.15,16 These two 
studies also showed that initial dietary management with an 
eHCF instead of an AAF affords a more cost-effective use of 
health care resources since it reduced costs and released health 
care resources for alternative use within the system without 
impacting on the time needed to manage the allergy.15,16
The Brazilian Food Allergy Guidelines recommend 8 
weeks of a diagnostic elimination diet with an extensively 
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hydrolyzed formula in infants <6 months of age prior to an 
oral food challenge.17 However, based on the interviews with 
31 pediatricians across Brazil, it would appear that the guide-
lines are not being followed by about one-third of general 
pediatricians and two-thirds of pediatric gastroenterologists. 
Moreover, according to our estimates, only 30% of all infants 
are referred to a pediatric specialist. The other 70% are man-
aged exclusively by a general pediatrician and less than half 
of these infants would undergo any type of diagnostic test. 
Moreover, they would not undergo an oral food challenge 
until they had been fed with a formula for 6, 9, or 12 months. 
This is consistent with the findings of others who reported that 
use of a food challenge has been limited.18 Instead, a diag-
nosis of food allergy is usually established based on clinical 
history, physical examination, presence of specific IgE, and 
restricted diets.18 Notwithstanding this, it is important to note 
that results from skin prick tests and measurements of specific 
IgE are markers of sensitization. The DBPCFC remains the 
standard for diagnosing food allergy.19 However, given the 
time-intensive nature of the DBPCFC, a single-blind or open 
food challenge is used more often in clinics in Brazil. This 
reflects the practical difficulty of performing challenges on 
non-IgE-mediated allergic infants who may react as late as 
1 or 2 weeks to a cow’s milk protein challenge.
It has been reported that using an AAF as a diagnostic 
tool for CMA followed by treatment according to current 
practice is cost-effective, when compared with managing 
infants according to current practice in Brazil.20,21 However, 
this analysis20,21 assumed that all infants treated with an 
AAF would be successfully managed and it did not account 
for differences in the probability of tolerance acquisition to 
cow’s milk between different formulas. It has been shown in 
clinical practice that fewer infants fed with an AAF acquire 
tolerance to cow’s milk than those fed with an eHCF, a 
soy formula, or a hydrolyzed rice formula.8 Also, findings 
from a recent DBPCFC study found an estimated 50% of 
infants aged <4 months remained symptomatic on an AAF.22 
 Furthermore, in our UK study of 295 infants with CMA who 
were followed up for a year,16 more AAF-treated infants 
received prescriptions for short-term use of bronchodilators 
than eHCF-treated infants (odds ratio 2.4 [95% confidence 
 interval: 1.09; 5.29]; P<0.03), although patients in both 
groups were matched (Guest et al, unpublished data, 2012). 
This difference in requirement for bronchodilators may be 
indicative of a propensity to develop respiratory disease, 
and warrants further research. Accordingly, the costs esti-
mated in the study on using an AAF as a diagnostic tool,20,21 
particularly those for infants being fed with an extensively 
hydrolyzed formula, are likely to have been overestimated, 
since costs were attributed to patient management when 
infants are likely to have acquired tolerance to cow’s milk and 
no longer require a hypoallergenic formula. Consequently, 
their estimate of symptom-free days20,21 is potentially inac-
curate, as is their conclusion.20,21 According to our analysis, 
feeding an AAF to a suspected CMA infant for 4 weeks and 
then switching to an eHCF would increase resource use and 
the corresponding SUS costs by 11%, when compared with 
using an eHCF as the initial formula. It would also reduce the 
probability of acquiring tolerance to cow’s milk at 12 months 
from starting a formula by 8%.
Our economic analysis has several limitations. The deci-
sion models may not necessarily reflect the clinical outcomes 
associated with managing a large cohort of infants in clinical 
practice. The models were informed with assumptions about 
treatment patterns from 31 pediatricians, who are based 
at different centers in eleven different towns/cities across 
 Brazil. Hence, the estimated levels of health care resource 
use incorporated into the models may not be representa-
tive of the whole of Brazil. Also, the models were based 
on clinical outcomes from an Italian study,8 which may not 
necessarily be reproducible in Brazil. Hence, a controlled 
study of alternative formulas is required to assess tolerance 
acquisition to cow’s milk among allergic infants in Brazil, 
in order to validate the measures of clinical effectiveness in 
this study. The analysis estimated the cost-effectiveness of 
managing infants up to 12 months from starting a formula 
and does not consider the potential impact of managing 
infants who remain allergic beyond that period. Infants with 
comorbidities were excluded from the observational study.8 
Hence, this economic analysis does not consider the impact 
that factors such as comorbidities, underlying disease sever-
ity, and pathology of underlying disease may have on the 
results. Also, the analysis does not consider the suitability 
of infants to receive different formulae. Only direct health 
care costs borne by the SUS have been estimated and indirect 
costs incurred by society as a result of employed parents tak-
ing time off work were excluded. Also, changes in quality of 
life and improvements in general well-being of sufferers and 
their parents, as well as parents’ preferences were excluded. 
Consequently, this study may have underestimated the rela-
tive cost-effectiveness of an eHCF.
Despite these limitations, the analysis showed that propor-
tionally more infants in Brazil who are initially fed with an 
eHCF are likely to develop tolerance to cow’s milk compared 
to those initially fed with an AAF, over the initial 12 months 
after starting a formula. Furthermore, infants who develop 
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tolerance to cow’s milk no longer require any management 
or feeding with a hypoallergenic formula. Consequently, 
initially feeding an eHCF to the annual cohort of 70,750 
new CMA-affected infants in Brazil, instead of the current 
mix of formulas, has the potential to increase the percentage 
of infants developing tolerance to cow’s milk from 42% to 
50%. It also has the potential to lead to a reduction of 27,300 
pediatrician visits and decrease in health service costs by up 
to R$ 126.9 million. Hence, initially using an eHCF to treat 
cow’s milk allergic infants has the potential to release health 
care resources for alternative use within the system.
For the purpose of the budget impact analysis, the annual 
incidence of CMA was assumed to be 0.025.13 However, 
the actual epidemiology of CMA in Brazil is unknown. 
Furthermore, an increasing number of patients in Brazil are 
developing allergies to local foods such as pineapple, papaya, 
pequi, and manioc.2 Reference centers have now been created 
to support the increasing demand of food allergy, offering 
allergy training programs that include clinical experience in 
oral food challenges and other diagnostic tests.
Conclusion
Within the study’s limitations, first-line management of newly-
diagnosed cow’s milk allergic infants with an eHCF instead 
of an AAF affords a cost-effective use of publicly funded 
resources, since it improves outcome, releases health care 
resources for alternative use, and reduces costs to the SUS.
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